IVA.PA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:35):

Stats
Dzisiejszy wolumen	37 188.00
Średni wolumen	66 924.00
Kapitalizacja rynkowa	165.49M
EPS	€0 ( 2024-03-28 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-1.300
ATR14	€0.0110 (0.35%)

Wolumen Korelacja

Długi: -0.05 (neutral)

Krótki: -0.36 (neutral)

Signal:(48.529) Neutral

Inventiva SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Inventiva SA Korelacja - Waluta/Towar

-0.60
( weak negative )

-0.81
( strong negative )

0.00
( neutral )

-0.78
( moderate negative )

0.68
( moderate )

0.63
( weak )

Inventiva SA Finanse

Annual	2023
Przychody:	€17.48M
Zysk brutto:	€17.50M (100.13 %)
EPS:	€-2.43

FY	2023
Przychody:	€17.48M
Zysk brutto:	€17.50M (100.13 %)
EPS:	€-2.43

FY	2022
Przychody:	€12.18M
Zysk brutto:	€11.18M (91.83 %)
EPS:	€-1.310

FY	2021
Przychody:	€4.19M
Zysk brutto:	€0.00 (0.00 %)
EPS:	€-1.465

Financial Reports:

No articles found.

Inventiva SA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.